Cantor Fitzgerald Investment Advisors L.P. Has $11.78 Million Stock Position in Pfizer Inc. $PFE

Key Points

• Cantor Fitzgerald Investment Advisors cut its Pfizer stake by 13.6%, selling 74,208 shares and finishing the quarter with 472,976 shares valued at $11.78 million.
• Institutional investors own 68.36% of Pfizer, and several large funds (State Street, Northern Trust, Fisher, Legal & General, Amundi) have recently increased positions—State Street now holds roughly 299.1 million shares (~$7.62 billion).
• Analyst and market signals are mixed: Pfizer beat Q4 EPS estimates ($0.66 vs. $0.57) and carries a consensus "Hold" rating with a $28.14 target, while firm-level views range from BMO's $30 outperform to Barclays' $25 underweight.

Cantor Fitzgerald Investment Advisors L.P. lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 13.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 472,976 shares of the biopharmaceutical company's stock after selling 74,208 shares during the period. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Pfizer were worth $11,777,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp boosted its position in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock valued at $7,620,747,000 after buying an additional 2,786,098 shares in the last quarter. Northern Trust Corp boosted its position in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock valued at $1,631,225,000 after buying an additional 869,175 shares in the last quarter. Fisher Asset Management LLC boosted its position in Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock valued at $1,255,860,000 after buying an additional 897,786 shares in the last quarter. Legal & General Group Plc boosted its position in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock valued at $1,063,565,000 after buying an additional 3,296,415 shares in the last quarter. Finally, Amundi boosted its position in Pfizer by 10.8% in the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock valued at $1,096,380,000 after buying an additional 4,043,413 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Morgan Stanley raised its price target to $28 and kept an "equal weight" rating, implying modest upside and signaling some confidence in near-term fundamentals. Morgan Stanley raises PFE price target (Benzinga)
• Positive Sentiment: MarketWatch noted a recent intraday uptick (but continued underperformance versus the broader market), which can attract short-term buyers looking for mean-reversion after pullbacks. Pfizer Inc. stock rises Wednesday (MarketWatch)
• Neutral Sentiment: Zacks flagged Pfizer as a "trending" stock, meaning elevated retail/institutional attention — this can increase volatility but doesn’t by itself indicate direction. Pfizer is a trending stock (Zacks)
• Neutral Sentiment: Coverage pieces (Yahoo/MSN) are re-examining Q4 earnings, one-year performance and valuation after a strong one‑year gain; these narratives shape whether investors view PFE as fairly valued or still a buy. Is Pfizer Offering Value (Yahoo) Q4 earnings highs and lows (MSN)
• Neutral Sentiment: Pfizer announced its virtual Annual Meeting on April 23; routine corporate governance items can temper short-term trading but are unlikely to change fundamentals. Annual meeting webcast (BusinessWire)
• Neutral Sentiment: Industry research on the biopharmaceutical CXO market cites Pfizer among large players navigating outsourcing and supply-chain trends — a background macro theme that could help longer-term margins but is not an immediate catalyst. Biopharmaceutical CXO market report (Yahoo/GlobeNewswire)
• Negative Sentiment: Bank of America cut its price target to $26 and moved to "neutral," signaling downside risk and adding selling pressure from model-driven desks. Bank of America lowers PFE PT (Benzinga)
• Negative Sentiment: Zacks ran a comparative piece showing AbbVie (ABBV) pulling ahead on strong growth from Skyrizi and Rinvoq, underscoring competitive headwinds in immunology that could pressure Pfizer’s growth multiple. AbbVie vs Pfizer growth comparison (Zacks)
• Negative Sentiment: Coverage explaining why Pfizer tumbled earlier in the week highlights mixed near-term signals (analyst downgrades, rotation to other healthcare names), which can prolong weak sentiment even after small positive data points. Why Pfizer stock tumbled (Yahoo)

Analyst Ratings Changes

A number of equities analysts have recently commented on PFE shares. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Thursday, January 22nd. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Thursday. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an "underweight" rating and a $25.00 price target on the stock. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an "underperform" rating in a report on Wednesday, December 17th. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $28.14.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.91 on Friday. Pfizer Inc. has a twelve month low of $21.28 and a twelve month high of $28.75. The firm has a fifty day simple moving average of $27.20 and a 200 day simple moving average of $25.93. The company has a market capitalization of $152.99 billion, a PE ratio of 19.78 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm earned $0.63 earnings per share. Pfizer's quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.